Why It Matters
Unicycive Therapeutics Inc. signed a new lobbying registration on Nov. 6 with KPM Group DC LLC, according to its new client registration. The filing lists Health Issues (HCR) and describes the work as "kidney care, FDA approval processes and chronic kidney disease advocacy."
The client already has a second outside firm. Arnold & Porter Kaye Scholer LLP filed a new client registration in 2026 and has no termination. Lester Health Law PLLC reported through the fourth quarter of 2025, when it filed a termination effective Oct. 1, 2025.
By the Numbers
Arnold & Porter Kaye Scholer LLP reported $40,000 in its third-quarter report. Lester Health Law PLLC reported $0 for the third quarter of 2025 and $20,000 for the second quarter of 2025. Its first-quarter report of 2025 shows $20,000.
The KPM Group filing carries a $0 filing amount. It lists three lobbyists: Josh Taggart (Senior Manager, Public Affairs), Patroski Lawson (Founder/Chief Executive Officer) and Sarina Neote (Senior Director of Public Affairs).
Broader Context
Unicycive Therapeutics said on Oct. 21 that the Food and Drug Administration (FDA) accepted its application for oxylanthanum carbonate, an oral phosphate binder for dialysis patients with chronic kidney disease, and set a March 25, 2027 target action date, according to the company's announcement. Its Sept. 29 release said a June complete response letter cited deficiencies at the original third-party manufacturer.
The Congress.gov record shows H.R. 6214, the Kidney Care Access Protection Act, introduced Nov. 20, 2025, and still at the introduced stage. It would extend the transitional drug add-on payment adjustment to at least three years for qualifying new renal-dialysis drugs.
The Centers for Medicare & Medicaid Services said in a fact sheet that it would pay 100% of average sales price plus $36.41 for oral-only phosphate binders under that adjustment from Jan. 1, 2025.
Competitive Landscape
Three other organizations recently registered on Health Issues (HCR) through other firms:
Whidbey Health hired Johnston Group on Nov. 6. Pharmaceutical Care Management Association hired Indigo Hill Strategies on Nov. 6. Immix Biopharma Inc. hired Brownstein Hyatt Farber Schreck LLP on Nov. 4.
The Bottom Line
The registration puts a second outside firm on the client's kidney and FDA work. It adds representation without naming any legislation.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article
